BridgeBio Pharma (BBIO) Non-Current Deffered Revenue (2023 - 2026)

BridgeBio Pharma (BBIO) has 4 years of Non-Current Deffered Revenue data on file, last reported at $11.8 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Deffered Revenue fell 32.74% year-over-year to $11.8 million; the trailing twelve-month figure through Mar 2026 stood at $11.8 million (down 32.74% YoY), and the FY2025 full-year result was $13.1 million, down 23.49% from the prior year.
• Non-Current Deffered Revenue declined to $11.8 million in Q1 2026, from $13.1 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $19.9 million in Q1 2024 to a low of $3.7 million in Q4 2023.
• A 4-year average of $14.6 million and a median of $15.8 million in 2024 frame the typical range for Non-Current Deffered Revenue.
• Across the five-year window, Non-Current Deffered Revenue jumped 358.68% in 2024 and slumped 32.74% in 2026, its largest moves.
• Tracing BBIO's Non-Current Deffered Revenue over 4 years: stood at $3.7 million in 2023, then jumped by 358.68% to $17.1 million in 2024, then fell by 23.49% to $13.1 million in 2025, then slipped by 9.97% to $11.8 million in 2026.
• Business Quant data shows BBIO's Non-Current Deffered Revenue at $11.8 million in Q1 2026, $13.1 million in Q4 2025, and $13.1 million in Q3 2025.